News | PET Imaging | June 22, 2016

FDG PET Evaluates Immunotherapy for Non-Small Cell Lung Cancer

Molecular imaging is used to monitor a novel immunotherapy that aims to hamper tumors’ ability to turn off cancer-fighting immune cells

NSCLC, lung cancer, chemotherapy, FDG PET, SNMMI 2016

June 22, 2016 — Non-small cell lung cancers (NSCLC) have a collective reputation for not responding very well to chemotherapy. Researchers at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 11-15 in San Diego, presented a means of evaluating an immunotherapy that fights off NSCLC by strengthening a patient’s own immune system.

NSCLC accounts for as much as 85 percent of all lung cancers. Due to NSCLC’s relative insensitivity to chemotherapy, researchers have been increasing the use of immunotherapies, including a class of monoclonal antibodies that serve as immune checkpoint blockade inhibitors. Essentially, these drugs stop malignant tumor cells from hijacking aspects of the immune system that keep cancer cells from proliferating out of control. Here, researchers investigated a relatively new drug called atezolizumab, which inhibits activity between the programmed death 1 (PD-1) receptor expressed on certain immune cells — most notably killer T cells — and the programmed death-ligand 1 (PD-L1), a transmembrane protein found on the surface of tumor cells. Cancer and other antigen-bearing cells wield this protein to bind with and deactivate cancer-specific T cells and effectively suppress immune response to malignant cells.

Researchers tracked the ability of atezolizumab to bolster immunity against NSCLC with positron emission tomography (PET), which provides a visualization of physiological functions of the body with the aid of an injected imaging agent combining a tiny amount of radioactive material and a molecular compound called fluorine-18 fluorodeoxyglucose (F-18 FDG). This radiotracer mimics glucose as it is taken up as fuel by the body. FDG-PET allows clinicians to see areas of increased metabolic activity in cells, also known as hypermetabolism, a hallmark of malignant tissues, and change in metabolic activity following drug treatment.

“This study is the first to prospectively evaluate FDG-PET imaging in a phase II trial of lung cancer patients receiving the novel immune checkpoint inhibitor atezolizumab,” said Jill Fredrickson, Ph.D., a clinical imaging scientist in the Department of Early Clinical Development at Genentech in San Francisco, Calif. “These findings help define the potential role of FDG-PET as a prognostic and predictive biomarker in the treatment of lung cancer with such immuno-therapeutics.”

This multi-center study included a total of 138 patients with NSCLC from 28 clinical institutions in five different countries. All subjects received 1,200 mg of atezolizumab administered intravenously in three-week intervals. Researchers used quantitative PET that measured FDG retention as a sign of metabolic activity, both at baseline before study treatment, and again after six weeks of treatment with atezolizumab.

The study revealed that higher baseline tumor volumes of FDG were predictive of reduced patient survival, meaning that greater active tumor volume at the start of therapy was a sign of lower survival. In addition, a further increase in tumor volume at six weeks was a sign of decreased patient survival. Although atezolizumab and other immune checkpoint inhibitors work differently than conventional chemotherapy, FDG-PET may be used with either treatment to help doctors evaluate how NSCLC patients may respond to therapy.

For more information: www.snmmi.org

Related Content

FDA Clears Ion Endoluminal Lung Biopsy System
Technology | Interventional Radiology | February 20, 2019
The U.S. Food and Drug Administration (FDA) cleared the Ion endoluminal system from Intuitive Surgical Inc. to enable...
Videos | Radiation Therapy | February 15, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
Micro-Ultrasound and Artificial Intelligence Combining to Detect Prostate Cancer
News | Prostate Cancer | February 12, 2019
Cambridge Consultants has partnered with Exact Imaging, makers of the ExactVu micro-ultrasound platform, as the two...
An example of Philips' TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal.

An example of Philips' TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal. 

Feature | Ultrasound Imaging | February 07, 2019 | Dave Fornell, Editor
Here is a list of six key trends in ul...
Oxford University Hospitals Employs Barco Synergi for Multi-disciplinary Cancer Conferences
News | Oncology Diagnostics | February 06, 2019
Oxford University Hospitals (OUH) is trialing clinical collaboration technology from Barco for its Multi-disciplinary...
Podcast | Cybersecurity | February 04, 2019
Cyber hackers pose a worsening threat to radiology and the rest of medical imaging.
The top article from January was about researchers in Sweden using computed tomography (CT) to image the soft tissue of an ancient Egyptian mummy’s hand down to a microscopic level. Non-destructive imaging of human and animal mummies with X-rays and CT has been a boon to the fields of archaeology and paleopathology. Most popular radiology articles and news in January 2019.

The top article from January was about researchers in Sweden using computed tomography (CT) to image the soft tissue of an ancient Egyptian mummy’s hand down to a microscopic level. Non-destructive imaging of human and animal mummies with X-rays and CT has been a boon to the fields of archaeology and paleopathology.

Feature | February 01, 2019 | A.J. Connell and Dave Fornell
February 1, 2019 — Here is the list of the most popular content on the Imaging Technology News (ITN) magazine website
ImaginAb Enrolls First Patient in Phase II PET Agent Clinical Trial
News | Radiopharmaceuticals and Tracers | January 30, 2019
ImaginAb Inc. announced the enrollment of the first patient in the Phase II clinical trial of the company’s CD8+ T Cell...
Videos | Lung Cancer | January 29, 2019
Gregory Videtic, M.D., staff physician in radiation oncology at the Cleveland Clinic, and David Johnstone, M.D., prof
In today’s digital environment, a radiologist only sees images saved and shared to the PACS, so a firm understanding of X-ray reject rates is crucial for high image quality and good workflow.

In today’s digital environment, a radiologist only sees images saved and shared to the PACS, so a firm understanding of X-ray reject rates is crucial for high image quality and good workflow.

Feature | Digital Radiography (DR) | January 29, 2019 | By Jeff Zagoudis
X-rays were the first medical imaging technology to be invented, and they remain one of the most commonly performed e